Fujirebio

Fujirebio is a global leader in the field of high-quality in vitro diagnostics (IVD), specialising in the research, development, manufacturing, and marketing of diagnostic testing solutions.

Established in Tokyo, Japan, in 1950, Fujirebio has amassed over 50 years of pioneering expertise in IVD. The company has grown through strategic acquisitions, including Centocor Diagnostics, CanAg Diagnostics, and Innogenetics, enhancing its global presence and product offerings. Fujirebio operates R&D and manufacturing facilities across Asia, Europe, and the United States, ensuring a robust international distribution network.

As an R&D-driven organisation, Fujirebio continually develops new technologies and unique biomarkers with high clinical value, aiming to create new value in healthcare and contribute to the future of medical care.

Key Products and Services

In Vitro Diagnostic (IVD) Solutions: Fujirebio offers a comprehensive range of manual and fully automated IVD testing solutions, covering areas such as infectious diseases, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration, and bone disorders.

Contract Development and Manufacturing Organisation (CDMO) Services: Fujirebio provides critical raw materials manufacturing, assay development, customisation, co-development, large-scale production, auditing, and continuous development of new biomarkers. These services support diagnostic companies from the initial concept to the finished product, ensuring high-quality and timely delivery.

With a rich history and unwavering commitment to innovation, Fujirebio continues to be at the forefront of the IVD industry. Its extensive expertise, global infrastructure, and comprehensive product and service offerings make it a trusted partner for healthcare providers and diagnostic companies worldwide.